Pitavastatin for the treatment of primary hyperlipidemia and mixed dyslipidemia

References

• Grundy SM, Cleeman JI, Merz CNB et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation110, 227–239 (2004).
   PubMed Web of Science ®Google Scholar
• Robinson JG, Smith B, Maheshwari N, Schrott H. Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis. J. Am. Coll. Cardiol.46, 1855–1862 (2005).
   PubMed Web of Science ®Google Scholar
• Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA285, 2486–2497 (2001).
   PubMed Web of Science ®Google Scholar
• Cholesterol Treatment Trialists’ Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet366, 1267–1278 (2005).
   PubMed Web of Science ®Google Scholar
• Gotto AM. Contemporary Diagnosis and Management of Lipid Disorders(4th Edition). Handbooks in Health Care, PA, USA (2008).
   Google Scholar
• Product information. Livalo (pitavastatin). Kowa Pharmaceuticals America, Inc., AL, USA (2009).
   Google Scholar
• Suzuki M, Iwasaki H, Fujikawa Y et al. Synthesis and biological evaluations of quinoline-based HMG-CoA reductase inhibitors. Bioorg. Med. Chem.9, 2727–2743 (2001).
   PubMed Web of Science ®Google Scholar
• Morikawa S, Umetani M, Nakagawa S et al. Relative induction of mRNA for HMG CoA reductase and LDL receptor by five different HMG-CoA reductase inhibitors in cultured human cells. J. Atheroscler. Thromb.7(3), 138–144 (2000).
   PubMedGoogle Scholar
• Kajinami K, Takekoshi N, Saito Y. Pitavastatin: efficacy and safety profiles of a novel synthetic HMG-CoA reductase inhibitor. Cardiovasc. Drug Rev.21(3), 199–215 (2003).
   PubMed Web of Science ®Google Scholar
• Hirano M, Maeda K, Shitara, Sugiyama Y. Drug–drug interaction between pitavastatin and various drugs via OATP1B1. Drug Metab. Dispos.34(7), 1229–1236 (2006).
   PubMed Web of Science ®Google Scholar
• Hirano M, Maeda K, Shitara Y, Sugiyama Y. Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J. Pharmacol. Exp. Ther.311(1), 139–146 (2004).
   PubMed Web of Science ®Google Scholar
• Voora D, Shah SH, Spasojevic I et al. The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J. Am. Coll. Cardiol.54(17), 1609–1616 (2009).
   PubMed Web of Science ®Google Scholar
• SEARCH Collaborative Group. SLCO1B1 variants and statin-induced myopathy – a genome-wide study. N. Engl. J. Med.359(8), 789–799 (2008).
   PubMed Web of Science ®Google Scholar
• Wen J, Xiong Y. OATP1B1 388A>G polymorphism and pharmacokinetics of pitavastatin in Chinese healthy volunteers. J. Clin. Pharm. Ther.35(1), 99–104 (2010).
   PubMed Web of Science ®Google Scholar
• Ieiri I, Suwannakul S, Maeda K et al.SLCO1B1 (OATP1B1, an uptake transporter) and ABCG2 (BCRP, an efflux transporter) variant alleles and pharmacokinetics of pitavastatin in healthy volunteers. Clin. Pharmacol. Ther.82(5), 541–547 (2007).
   PubMed Web of Science ®Google Scholar
• Hayashi T, Yokote K, Saito Y, Iguchi A. Pitavastatin: efficacy and safety in intensive lipid lowering. Exp. Opin. Pharmacother.8, 2315–2327 (2007).
   PubMed Web of Science ®Google Scholar
• Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin. Pharmacol. Ther.80(6), 565–581 (2006).
   PubMed Web of Science ®Google Scholar
• Shitara Y, Sugiyama Y. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug–drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol. Ther.112(1), 71–105 (2006).
   PubMed Web of Science ®Google Scholar
• Fujino H, Saito T, Tsunenari Y, Kojima J. Interaction between several medicines and statins. Arzneimittelforschung53(3), 145–153 (2003).
   PubMed Web of Science ®Google Scholar
• Ando H, Tsuroka S, Yanagihara H et al. Effects of grapefruit juice on the pharmacokinetics of pitavastatin and atorvastatin. Br. J. Clin. Pharmacol.60(5), 494–497 (2005).
   PubMed Web of Science ®Google Scholar
• Wensel TM, Waldrop BA, Wensel B. Pitavastatin: a new HMG-CoA reductase inhibitor. Ann. Pharmacother.144, 507–514 (2010).
   Google Scholar
• Sakaeda T, Fujino H, Komoto C et al. Effects of acid and lactone forms of eight HMG-CoA reductase inhibitors on CYP-mediated metabolism and MDR1-mediated transport. Pharm. Res.23(3), 502–512 (2005).
   Google Scholar
• Prueksaritanont T, Subramanian R, Fang X et al. Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization. Drug Metab. Disp.30(5), 505–512 (2002).
   PubMed Web of Science ®Google Scholar
• Prueksaritanont T, Zhao J, Ma B et al. Mechanistic studies on metabolic interactions between gemfibrozil and statins. J. Pharm. Exp. Ther.301(3), 1042–1051 (2002).
   PubMed Web of Science ®Google Scholar
• Prueksaritanont T, Tang C, Qui Y et al. Effects of fibrates on metabolism of statins in human hepatocytes. Drug Metab. Dispos.30(11), 1280–1287 (2002).
   PubMed Web of Science ®Google Scholar
• Fujino H, Saito T, Tsunenari Y, Kojima J. Effect of gemfibrozil on the metabolism of pitavastatin – determining the best animal model for human CYP and UGT activities. Drug Metabol. Drug Interact.20(1–2), 25–42 (2004).
   PubMedGoogle Scholar
• Holtzman CW, Wiggins BS, Spinler SA. Role of p-glycoprotein in statin drug interactions. Pharmacotherapy26(11), 1601–1607 (2006).
   PubMed Web of Science ®Google Scholar
• Wang E, Casciano CN, Clement RP, Johnson WW. HMG-CoA reductase inhibitors (statins) characterized as direct inhibitors of P-glycoprotein. Pharm. Res.18(6), 800–806 (2001).
   PubMed Web of Science ®Google Scholar
• Fujino H, Yamada I, Shimada S, Kojima J. Metabolic fate of pitavastatin, a new inhibitor of HMG-CoA reductase – effect of cMOAT deficiency on hepatobiliary excretion in rats and of mdr1a/b gene disruption on tissue distribution in mice. Drug Metab. Pharmacokinet.17(5), 449–456 (2002).
   PubMedGoogle Scholar
• Inagaki Y, Hunt T, Arana B et al. Drug–drug interaction study to assess the effects of multiple dose of pitavastatin (Livalo®) on steady-state warfarin in healthy adult volunteers. XV International Symposium on Atherosclerosis 2009. 14–18 June 2009, Boston, MA, USA. Atheroscler. Suppl.10(2), P493 (2009).
   Google Scholar
• Kajinami K, Mabushi H, Saito Y. NK-104: a novel synthetic HMG-CoA reductase inhibitors. Exp. Opin. Invest. Drugs9(11), 2653–2661 (2000).
   PubMed Web of Science ®Google Scholar
• Saito Y, Yamada N, Teramoto T et al. Clinical efficacy of pitavastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in patients with hyperlipidemia. Arzneimittelforschung52, 251–255 (2002).
   PubMed Web of Science ®Google Scholar
• Saito Y, Yamada N, Teramoto T, Itakura H et al. A randomized, double-blind trial comparing the efficacy and safety of pitavastatin versus pravastatin in patients with primary hypercholesterolemia. Atherosclerosis162(2), 373–379 (2002).
   PubMed Web of Science ®Google Scholar
• Kajinami K, Koizumi J, Ueda K et al.; Hokuriku NK-104 study group. Effects of NK-104, a new hydroxymethylglutaryl-coenzyme reductase inhibitor, on low-density lipoprotein cholesterol in heterozygous familial hypercholesterolemia. Am. J. Cardiol.85(2), 178–183 (2000).
   PubMed Web of Science ®Google Scholar
• Noji Y, Higashikata T, Inazu A et al.; Hokuriku NK-104 study group. Long-term treatment with pitavastatin (NK-104), a new HMG-CoA reductase inhibitor, of patients with heterozygous familial hypercholesterolemia. Atherosclerosis163(1), 157–164 (2002).
   PubMed Web of Science ®Google Scholar
• Sone H, Takahashi A, Shimano H et al. HMG-CoA reductase inhibitor decreases small dense low-density lipoprotein and remnant-like particle cholesterol in patients with Type 2 diabetes. Life Sci.71(20), 2403–2412 (2002).
   PubMed Web of Science ®Google Scholar
• Park S, Kang HJ, Rim SJ et al. A randomized, open-label study to evaluate the efficacy and safety of pitavastatin compared with simvastatin in Korean patients with hypercholesterolemia. Clin. Ther.27, 1074–1082 (2005).
   PubMed Web of Science ®Google Scholar
• Budinski D, Arneson V, Hounslow N, Gratsiansky N. Pitavastatin compared with atorvastatin in primary hypercholesterolemia or combined dyslipidemia. Clin. Lipidol.4(3), 291–302 (2009).
   Web of Science ®Google Scholar
• Ose L, Budinski D, Hounslow N, Arneson V. Comparison of pitavastatin with simvastatin in primary hypercholesterolemia or combined dyslipidemia. Curr. Med. Res. Opin.25(10), 2755–2764 (2009).
   PubMed Web of Science ®Google Scholar
• Kurihara Y, Douzono T, Kawakita K. A large-scale, long-term, prospective post-marketing surveillance of pitavastatin: LIVALO effectiveness and safety (LIVES) study. Jpn Pharmacol. Ther.36(8), 709–731 (2008).
   Google Scholar
• Teramoto T, Shimano H, Yokote K, Urashima M. New evidence on pitavastatin: efficacy and safety in clinical studies. Expert Opin. Pharmacother.11(5), 817–828 (2010).
   PubMed Web of Science ®Google Scholar
• Yokote K, Bujo H, Hanaoka H et al. Multicenter collaborative randomized parallel group comparative study of pitavastatin and atorvastatin in Japanese hypercholesterolemic patients. Collaborative study on hypercholesterolemia drug intervention and their benefits for atherosclerosis prevention (CHIBA study). Atherosclerosis201, 345–352 (2008).
   PubMed Web of Science ®Google Scholar
• Koshiyama H, Taniguchi A, Tanaka K et al. Effects of pitavastatin on lipid profiles and high-sensitivity CRP in Japanese subjects with hypercholesterolemia: Kansai investigation of statin for hyperlipidemic intervention in metabolism and endocrinology (KISHIMEN) investigators. J. Atheroscler. Thromb.15, 345–350 (2008).
   PubMed Web of Science ®Google Scholar
• Sasaki J, Ikeda Y, Kuribayashi T et al. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvatatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance. Clin. Ther.30, 1089–1101 (2008).
   PubMed Web of Science ®Google Scholar
• Hiro T, Kimura T, Morimoto T et al. Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome. J. Am. Coll. Cardiol.54(4), 293–302 (2009).
   PubMed Web of Science ®Google Scholar
• Nakamura T, Obata JE, Kitta Y et al. Rapid stabilization of vulnerable carotid plaque within 1 month of pitavastatin treatment in patients with acute coronary syndrome. J. Cardiovasc. Pharmacol.51(4), 365–371 (2008).
   PubMed Web of Science ®Google Scholar
• Morikawa S, Takabe W, Mataki C et al. The effect of statins on mRNA levels of genes related to inflammation, coagulation, and vascular constriction in HUVEC. J. Atheroscler. Thromb.9(4), 178–183 (2002).
   PubMedGoogle Scholar
• Jiang M, Bujo H, Zhu Y et al. Pitavastatin attenuates the PDGF-induced LR11/uPA receptor-mediated migration of smooth muscle cells. Biochem. Biophys. Res. Commun.348, 1367–1377 (2006).
   PubMed Web of Science ®Google Scholar
• Kaneyuki U, Ueda S, Yamagishi S et al. Pitavastatin inhibits lysophosphatidic acid-induced proliferation and monocyte chemoattractant protein-1 expression in aortic smooth muscle cells by suppressing Rac-1-mediated reactive oxygen species generation. Vascul. Pharmacol.46, 286–292 (2007).
   PubMed Web of Science ®Google Scholar
• Akisato Y, Ishii I. Effect of pitavastatin on macrophage cholesterol metabolism. Yakugaku Zasshi128, 357–363 (2008).
   PubMed Web of Science ®Google Scholar
• Abe M, Matsuda M, Kobayashi H et al. Effects of statins on adipose tissue inflammation: their inhibitory effect on MYD88-independent IRF3/IFN b pathway in macrophages. Arterioscler. Thromb. Vasc. Biol.28, 871–877 (2008).
   PubMed Web of Science ®Google Scholar
• Ohnaka K, Shimoda S, Nawata H et al. Pitavastatin enhanced BMP-2 and osteocalcin expression by inhibition of Rho-associated kinase in human osteoblasts. Biochem. Biophys. Res. Commun.287(2), 337–342 (2001).
   PubMed Web of Science ®Google Scholar
• Han J, Zhou X, Yokoyama T, Hajjar DP, Gotto AM, Nicholson AC. Pitavastatin downregulates expression of the macrophage type B scavenger receptor, CD36. Circulation109, 790–796 (2004).
   PubMed Web of Science ®Google Scholar
• Han J, Parsons M, Zhou X, Nicholson AC, Gotto AM, Hajjar DP. Functional interplay between the macrophage scavenger receptor class B type I and pitavastatin (NK-104). Circulation110, 3472–3479 (2004).
   PubMed Web of Science ®Google Scholar
• Lamon BD, Summers BD, Gotto AM, Hajjar DP. Pitavastatin suppresses mitogen activated protein kinase-mediated Erg-1 induction in human vascular smooth muscle cells. Eur. J. Pharmacol.606, 72–76 (2009).
   PubMed Web of Science ®Google Scholar
• Markle RA, Han J, Summers BD. Pitavastatin alters the expression of thrombotic and fibrinolytic proteins in human vascular cells. J. Cell. Biochem.90, 23–32 (2003).
   PubMed Web of Science ®Google Scholar
• Nicholson AC, Hajjar DP, Zhou X, He W, Gotto AM, Han J. Anti-adipogenic action of pitavastatin occurs through the coordinate regulation of PPARγ and Pref-1 expression. Br. J. Pharmacol.151, 807–815 (2007).
   PubMed Web of Science ®Google Scholar
• Armitage J. The safety of statins in clinical practice. Lancet370(9601), 1781–1790 (2007).
   PubMed Web of Science ®Google Scholar
• Sattar N, Preiss D, Murray HM et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomized statin trials. Lancet375(9716), 735–742 (2010).
   PubMed Web of Science ®Google Scholar
• Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet371, 117–125 (2008).
   PubMed Web of Science ®Google Scholar
• Ose L, Budinski D, Hounslow N, Arneson V. Long-term treatment with pitavastatin is effective and well tolerated by patients with primary hypercholesterolemia or combined dyslipidemia. Atherosclerosis210(1), 202–208 (2010).
   PubMed Web of Science ®Google Scholar
• Ridker PM, Danileson E, Fonseca FA et al.; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med.359(21), 2195–2207 (2008).
   PubMed Web of Science ®Google Scholar
• Product information. Lipitor (atorvastatin). Pfizer, NY, USA (2009).
   Google Scholar
• Product information. Lescol, Lescol XL (fluvastatin). Novartis Pharmaceuticals Corporation, NJ, USA (2006).
   Google Scholar
• Product information. Mevacor (lovastatin). Merck, NJ, USA (2008).
   Google Scholar
• Product information. Pravachol (pravastatin). Bristol-Myers Squibb, NJ, USA (2007).
   Google Scholar
• Product information. Crestor (rosuvastatin). AstraZeneca, DE, USA (2010).
   Google Scholar
• Product information. Zocor (simvastatin). Merck, NJ, USA (2008).
   Google Scholar